Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis

Rheumatology (Oxford). 2000 Feb;39(2):182-4. doi: 10.1093/rheumatology/39.2.182.

Abstract

We describe a 37-yr-old Caucasian male suffering from ankylosing spondylitis (AS) with long-standing severe inflammatory lumbar pain and hip arthritis who was refractory to non-steroidal anti-inflammatory drugs, sulphasalazine and methotrexate up to 25 mg/week. In this patient, administration of an i.v. loading dose of azathioprine (AZA; 40 mg/kg for 36 h followed by 2 mg/kg oral AZA therapy) induced a dramatic response in his clinical condition. Indeed, objective and subjective clinical variables improved within 1 week and were corroborated by a decline in the levels of the inflammatory parameters; anaemia was reported at month 3 but was rapidly reversible. If confirmed, an i.v. loading dose of AZA could represent a valuable alternative in severe and refractory AS, but toxicity of this regimen should be carefully analysed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / administration & dosage*
  • Azathioprine / administration & dosage*
  • Blood Sedimentation
  • C-Reactive Protein / analysis
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance
  • Humans
  • Infusions, Intravenous
  • Male
  • Pain Measurement / drug effects
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood
  • Spondylitis, Ankylosing / drug therapy*
  • Thioguanine / blood
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • C-Reactive Protein
  • Thioguanine
  • Azathioprine